Developer · SPTX · United States

Seaport Therapeutics, Inc.

Clinical-stage biopharmaceutical company developing medicines for depression, anxiety, and other neuropsychiatric disorders. Its pipeline is built on the proprietary Glyph platform, which uses the intestinal lymphatic system to enable oral delivery of drugs with high first-pass metabolism; lead candidate is GlyphAllo (SPT-300), an oral prodrug of allopregnanolone.

seaporttx.com ↗

1compound
1program
1indication
Phase 2lead asset

Phase distribution

  • Phase 21

Modality

  • neuroactive_steroid 1

Mechanism focus

Pipeline (1)

Deals & partnerships

  • Apr 9, 2024Licensing dealPureTech transfers Glyph IP and the SPT-300 (formerly LYT-300) program to founded entity SeaportPureTech founded Seaport and transferred the Glyph platform intellectual property and several therapeutic candidates - including SPT-300, the oral allopregnanolone prodrug previously advanced at PureTech as LYT-300 - into Seaport at its April 9, 2024 launch. PureTech retains a 31.2% equity stake plus 3-5% tiered royalties on Glyph product net sales and modest milestone payments (per PureTech, as of June 5, 2026).GlyphAllo (SPT-300)source ↗

Recent activity

Trials recruiting · 2 recruiting of 2 sponsored

  • Phase 2SPT-300n=36031 sites · United States, Poland, Czechia

    An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

    Major Depressive Disorder (MDD)Major Depressive Disorder With Anxious DistressNCT07161700 ↗

  • Phase 2GlyphAllo (SPT-300)n=36059 sites · United States, Poland, Czechia

    Monotherapy Study of SPT-300 in Adults With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1)

    Major Depressive DisorderMajor Depressive Disorder With Anxious DistressNCT07065240 ↗

Competitive landscape

Other companies developing against Seaport Therapeutics, Inc.'s targets or indications.

Leadership & advisors (14)